Allergy Therapeutics plc Share Price

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. 16:35:18 26/04/2024 BST 5-day change 1st Jan Change
2.85 GBX 0.00% Intraday chart for Allergy Therapeutics plc +7.55% +14.00%

Financials

Sales 2022 72.77M 90.9M 7.28B Sales 2023 59.59M 74.43M 5.96B Capitalization 7.13M 8.91M 713M
Net income 2022 -13M -16.24M -1.3B Net income 2023 -43M -53.71M -4.3B EV / Sales 2022 1.7 x
Net cash position 2022 9.99M 12.47M 999M Net Debt 2023 21.14M 26.41M 2.11B EV / Sales 2023 0.47 x
P/E ratio 2022
-9.69 x
P/E ratio 2023
-0.16 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 6.79%
More Fundamentals * Assessed data
Dynamic Chart
1 week+7.55%
Current month-5.00%
1 month-5.00%
3 months+14.00%
6 months+96.55%
Current year+14.00%
More quotes
1 week
2.70
Extreme 2.7
3.00
1 month
2.65
Extreme 2.65
3.20
Current year
1.80
Extreme 1.8
3.20
1 year
0.80
Extreme 0.8
3.90
3 years
0.80
Extreme 0.8
40.50
5 years
0.80
Extreme 0.8
40.50
10 years
0.80
Extreme 0.8
40.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 30/06/09
Director of Finance/CFO - 31/03/22
Chief Tech/Sci/R&D Officer - 31/12/03
Members of the board TitleAgeSince
Director/Board Member 67 05/06/17
Chairman 73 30/09/10
Director/Board Member - 05/12/22
More insiders
Date Price Change Volume
26/04/24 2.85 0.00% 515,871
25/04/24 2.85 0.00% 850,862
24/04/24 2.85 +1.79% 919,062
23/04/24 2.8 -1.75% 948,754
22/04/24 2.85 +7.55% 668,040

Delayed Quote London S.E., April 26, 2024 at 04:35 pm

More quotes
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
More about the company